MEK Inhibition Leads to PI3K/AKT Activation by Relieving a Negative Feedback on ERBB Receptors
Year: 2012
Type: article
Abstract: The phosphoinositide 3-kinase (PI3K)/AKT and RAF/MEK/ERK signaling pathways are activated in a wide range of human cancers. In many cases, concomitant inhibition of both pathways is necessary to block proliferation and induce cell death and tumor shrinkage. Several feedback systems have been described in which inhibition of one intracellular pathway leads to activation of a parallel signaling pathway, thereby decreasing the effectiveness of single-agent targeted therapies. In this study, we describe a feedback mechanism in which MEK inhibition leads to activation of PI3K/AKT signaling in EGFR and HER2-driven cancers. We found that MEK inhibitor-induced activation of PI3K/AKT resulted from hyperactivation of ERBB3 as a result of the loss of an inhibitory threonine phosphorylation in the conserved juxtamembrane domains of EGFR and HER2. Mutation of this amino acid led to increased ERBB receptor activation and upregulation of the ERBB3/PI3K/AKT signaling pathway, which was no longer responsive to MEK inhibition. Taken together, these results elucidate an important, dominant feedback network regulating central oncogenic pathways in human cancer.
Source: Cancer Research
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: green
Funder: National Cancer Institute
Awards: Dana Farber/ Harvard Cancer Center SPORE in Gastrointestinal Cancer, MUC1-C Oncoprotein Evades Immune Destruction in Non-small Cell Lung Cancer, The Co-Clinical Trial Project, Erbb2 targeted antitumor strategies in breast cancer, Therapeutic strategies for specific subsets of KRAS mutant lung cancers, Dana-Farber/Harvard Cancer Center SPORE in Lung Cancer, Molecular mechanisms of PI3K activation in non-small cell lung cancer, SPORE in Breast Cancer, Molecular Pathogenesis of the Hamartoma Syndromes, Non-genomic resistance mechanisms in EGFR-mutant lung cancer, Dana-Farber/Harvard Cancer Center
OpenAlex ID: W2105437003
